Glioblastoma Idh-wildtype
📧 Sign up to get email alerts when something new happens for Glioblastoma Idh-wildtype.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma [Phase 1, Phase 2]
A clinical trial update on LMP744, an indenoisoquinolone Topoisomerase I inhibitor, being studied for recurrent glioblastoma (including IDH-…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma [Phase 1, Phase 2]
An update on a Phase 1/2 clinical trial evaluating ultrasound-induced opening of the blood-brain barrier in combination with albumin-bound p…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma [Phase 3]
A Phase 3 clinical trial is evaluating the addition of lomustine to standard of care for patients with MGMT methylated, IDH-wildtype gliobla…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma [Phase 2]
Clinical trial update for a Phase 2 study evaluating GI-102 alone or with pembrolizumab before surgery in patients with recurrent or progres…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial [Phase 1]
Phase 1 trial update for ERAS-801 in IDH-wildtype glioblastoma or astrocytoma with EGFR amplification or mutation; enrolling currently.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy [Phase 1]
Phase 1 trial evaluating allogeneic adipose-derived mesenchymal stem cells for recurrent glioblastoma or recurrent astrocytoma in patients u…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma [Phase 1, Phase 2]
This clinical trial update describes ongoing Phase 1/2 studies of Debio 0123 in combination with temozolomide for recurrent/progressive glio…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma [Phase 3]
Phase 3 clinical trial comparing temporally-modulated pulsed radiation therapy to standard radiation therapy for newly diagnosed IDH-wildtyp…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis [Phase 1, Phase 2]
An ongoing phase 1/phase 2 trial assessing the safety and efficacy of NEO212 in patients with diffuse astrocytoma (IDH-mutant), glioblastoma…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: A Clinical Trial of P134 Cells in Recurrent Glioblastoma [Phase 1, Phase 2]
Tasly's P134 Cells are being studied for recurrent glioblastoma with IDH-wildtype in a Phase 1/2 trial, currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma [Phase 2, Phase 3]
Clinical trial update comparing Cerebraca Wafer plus Temozolomide vs Temozolomide alone in recurrent glioblastoma with IDH-wildtype, across …
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma [Phase 2]
A Phase 2 clinical trial is investigating the combination of efineptakin alfa with pembrolizumab for recurrent glioblastoma and related high…
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: A Study of 177Lu-PSMA-617 in People With Gliomas [Phase 1]
A Phase 1 clinical trial is evaluating 177Lu-PSMA-617 in patients with gliomas and related subtypes and is currently recruiting.
-
CLINICAL_TRIALS research · 2025-10-23Clinical Trial Update: D2C7-IT + 2141-V11 Combination Post-resection in rGBM [Phase 1]
A Phase 1 trial evaluating the combination of D2C7-IT and 2141-V11 in post-resection recurrent glioblastoma, IDH-wildtype, is currently recr…
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma [Phase 2]
This clinical trial entry notes a Phase 2a study from Northwestern University evaluating ultrasound-based immune modulation for newly diagno…
-
CLINICAL_TRIALS research · 2025-07-25Clinical Trial Update: Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma [Phase 2]
Phase 2 open-label, single-arm trial evaluating metformin as adjunctive therapy in glioblastoma with IDH-wildtype; currently recruiting.